ExcepGen emerges from Y Combinator, taking aim at better proteins for drug discovery

It’s no secret that drug discovery is a difficult business, with the vast majority of small molecules entering the clinic never coming out the other side. There’s no one cause for this failure rate—it comes from a mix of factors. Enter ExcepGen, which is taking aim at a historically challenging one: the way we make proteins for drug discovery.